Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils.

The neuroprotective/neuronal rescue effects of selegiline are not exactly understood, and show great variability in clinical trials. In this study, the dose-dependence of neuronal rescue potency of selegiline and its analogue para-fluoro-selegiline (PFS) was investigated in gerbils. The compounds were tested in a transient global cerebral ischemia model. Selegiline expressed a bell-shaped, dose-response curve with high intrinsic activity (with greatest effect at 0.001 mg/kg), as opposed to PFS which shows a saturation profile. These findings indicate possible therapeutic differences between PFS and selegiline in the treatment of neurodegenerative disorders. Inhibition of progression of the disease (neuroprotective effect) and improvements of symptoms (MAO-B inhibition) may occur at the same dose level using PFS, while these doses are separated in case of selegiline.

Ultrastructural localization of Hsp-72 examined with a new polyclonal antibody raised against the truncated variable domain of the heat shock protein.

In spite of the intensive search for the determination of the continuously widening physiological and pathological roles of different stress proteins, their ultrastructural localization at the electron microscopic (EM) level has hardly been examined. As it becomes increasingly evident that the function and physiological effectiveness of stress proteins are highly dependent on their spatial location and their associations with diverse regulator proteins, the demand for morphological studies which can identify their detailed distribution within the cells is evident. The reason for the practical lack of studies carried out at the EM level, lies in the shortage of reagents with suitable specificity and avidity necessary for this type of examination. To create such a reagent, a polyclonal antibody was raised using a recombinant truncated form of the inducible Hsp-72 protein. The antibody was extensively characterized, using different immunochemical methods to determine and verify its specificity, and then it was tried in ultrastructural examinations. Using the new antibody, it was possible to analyze the intracellular distribution of Hsp-72 with the immunogold technique. The localization of Hsp-72 was demonstrated directly at the ultrastructural level in the cytoplasm (especially at the cisterns of the RER), in the nucleus (mainly around the heterochromatic regions) and at both sides of the nuclear envelope close to the membrane pores. Apart from these localizations, Hsp-72 was found in several membrane bordered intracellular structures, which mainly belong to the endosomal-lysosomal system. We provide the first morphological verification of the appearance of Hsp-72 on the surface of the cells. Also novel is the indication, that the stress protein may recycle from the cell surface using a common route which includes coated pits and the endosomal system.

Diprotin A, an inhibitor of dipeptidyl aminopeptidase IV(EC 3.4.14.5) produces naloxone-reversible analgesia in rats.

The dipeptidyl aminopeptidase IV (DP IV) inhibitor Diprotin A produces a full, dose-dependent, short-lasting and naloxone-reversible analgesia in the rat tail-flick test when given intracerebroventricularly, with an ED50 of 295 nmol/rat but it has no direct opioid agonist activity in the longitudinal muscle strip of guinea-pig ileum bioassay. Two of the potential DP IV substrates, morphiceptin and endomorphin 1, identified recently in bovine brain were also analgesic given by similar route. The action of endomorphin 1 was more potent (ED50 = 7.9 nmol/rat) and slightly but significantly more sustained than that of Diprotin A. Diprotin A neither potentiated nor prolonged the effect of a marginally analgesic dose of endomorphin 1. The distinct time course and the lack of potentiation indicate that in the analgesic effect of Diprotin A in rats the protection of a brain Tyr-Pro-peptide other than endomorphin 1 is involved.

Bimoclomol protects against vascular consequences of experimental subarachnoid hemorrhage in rats.

Bimoclomol (BRLP-42) is a novel antiischemic compound acting against peripheral vascular complications of diabetes mellitus (neuropathy, retinopathy, and nephropathy). In the present study the activity of bimoclomol was tested in experimental subarachnoid hemorrhage (SAH) and arachidonic acid (AA)-induced brain edema in rats to elucidate whether the compound may also have beneficial effect in cerebrovascular disturbances. For comparison, a neuroprotective AMPA antagonist, GYKI-52466, was examined. Injury caused by autologous intracranial blood injection or sodium-arachidonate was evaluated by the damage of blood-brain barrier (BBB) reflected in the extravasation of Evans blue dye into the cerebral tissue. Bimoclomol (2 x 2 mg/kg IV) markedly reduced, while GYKI-52466 (2 x 2 mg/kg IV) moderately diminished the extravasation produced by SAH (39.9%, p < 0.01 and 26.7%, p > 0.05, respectively). In the case of AA-induced brain edema, bimoclomol showed less pronounced (19.6%, p < 0.05) inhibitory action, and GYKI-52466 seemed to be more effective (34.2%, p < 0.05). These results suggest that bimoclomol may be active not only in peripheral micro- and macroangiopathy, but also in some types of cerebrovascular disorders.

Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice.

The time-course and pharmacological modulation of interleukin-1 (IL-1) production were investigated during zymosan induced peritonitis in mice. IL-1 alpha liberation was assessed by specific immunoassay (ELISA) and the IL-1 like bioactivity (sensitive to both alpha- and beta-forms of IL-1) was measured by a sensitive bioassay (D10G4.1 costimulation). I.p. injection of zymosan induced significant IL-1 release into the peritoneal exudate. The level peaked at 4 h and by 24 h dropped below the detection limit in both assays. The effects of the prototypical antiinflammatory drugs indomethacin (IND) and dexamethasone (DEX) and that of IX 207-887, a compound which has been reported to interfere primarily with IL-1 production, were also tested. DEX and IX 207-887 dose-dependently decreased the immunoassayable IL-1 alpha level and the IL-1 like bioactivity as well. However, IND had no suppressant effect. Thus, the data obtained by immunoassay and bioassay correlated well proving the suitability of zymosan peritonitis model for the examination of IL-1 production in experimental inflammation.

Measurement of interleukin-1 liberation in zymosan air-pouch exudate in mice.

The aim of the present study was to examine whether interleukin-1 (IL-1) production is involved in the pathology of inflammation induced by zymosan in the air-pouch of mice. For this reason the IL-1 alpha level was determined in the air-pouch exudate by specific ELISA kit 4, 24, 48 h and 4-8 days after zymosan injection into preformed subcutaneous air-pouches in mice. Concurrently, some conventional parameters such as volume of exudate, its protein content and the total leukocyte count were also measured. The IL-1 alpha level reached its maximum 24 h after zymosan administration and remained elevated throughout the 8-day observation period. Exudation, accumulation of leukocytes and protein also were maximal on day 8. The effects of some anti-inflammatory agents have also been examined. Orally administered dexamethasone induced a dose-dependent reduction in IL-1 alpha, whereas indomethacin and IX 207-887, an IL-1-release inhibitor, failed to reduce the IL-1 alpha content in this model.

A new assay for antiphlogistic activity: zymosan-induced mouse ear inflammation.

A new model of local inflammation has been developed: intradermal zymosan-induced mouse ear edema. The symptoms of inflammation induced by injecting zymosan into one of the ears were followed up for 72 h. The ear edema and the local accumulation of polymorphonuclear leukocytes' (PMN) marker enzyme, myeloperoxidase (MPO), were determined. Edema peaked at 4-6 h, while MPO activity peaked at 24 h after zymosan application. The correlation between inflammatory response and concentration of zymosan was also tested. Of the various concentrations tested, 1% suspension has been found optimal. Anti-inflammatory drugs and mediator antagonists were examined in order to establish the selectivity and sensitivity of the assay. A glucocorticoid (dexamethasone), two cyclooxygenase inhibitors (indomethacin, piroxicam) and an interleukin-1 (IL-1) release inhibitor (IX 207-887, Sandoz) all reduced edema and MPO activity as well. However, a lipoxygenase inhibitor (phenidone), a serotonin receptor antagonist (methysergide) and H1 and H2 receptor antagonists (clemastine and cimetidine, respectively) all failed to inhibit the reaction.

Modulation of dopamine-induced hypermotility following injection of various opioids into the nucleus accumbens.

The aim of the present work was to obtain some data on the eventual role of nucleus accumbens in the antidopamine action of some opioids. Classical neuroleptics are known to inhibit the dopamine-elicited hypermotility when injecting them into the nucleus accumbens of rats pretreated with MAO inhibitors. In the present study the effects of some opioids have been examined in this model. The opioids examined were morphine, a mu-selective classical opiate, D-Ala2, Nle5-enkephalin sulphonic acid (ES), a delta selective opioid peptide and D-Met2, Pro5-enkephalinamide (EA), a non-selective opioid peptide. Haloperidol and chlorpromazine have been used for comparison. EA and morphine, especially the former, potently antagonized the dopamine-induced hyperactivity, similarly to haloperidol and chlorpromazine. ES exerted biphasic effect, the initial inhibition was followed by potentiation of the dopamine-elicited excitation. Thus the order of potency was: EA greater than haloperidol approximately equal to morphine greater than chlorpromazine greater than EA. The data indicate that the antidopamine action of opioids might be mediated, at least in part, by mu-receptors in the nucleus accumbens.